Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03937154 · ClinicalTrials.gov registry record · Phase 3

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

A Phase 3 study of Chemotherapy Induced Thrombocytopenia, sponsored by Amgen.

Active
Registry status
Phase 3
Development phase
145
Enrollment target
20
Study locations

NCT03937154 is a Phase 3 study of Chemotherapy Induced Thrombocytopenia that is active but no longer recruiting, run by Amgen. The registered enrollment target is 145 participants, above the 79-participant average among 4 other Chemotherapy Induced Thrombocytopenia trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03937154, a Phase 3 study of Chemotherapy Induced Thrombocytopenia, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
145 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Conditions Studied

Chemotherapy Induced Thrombocytopenia

Interventions

  • DRUG Placebo
  • DRUG Romiplostim

Study Locations (20)

Florida

  • University of Miami School of Medicine - Miami
  • Ocala Oncology Center - Ocala
  • Mid Florida Hematology and Oncology Centers PA - Orange City

Louisiana

  • Christus Saint Frances Cabrini Hospital - Alexandria
  • University Medical Center New Orleans - New Orleans
  • Christus Highland Cancer Treatment Center - Shreveport

California

  • Los Angeles Cancer Network - Anaheim
  • University of California Irvine - Orange

Illinois

  • University of Chicago - Chicago
  • Orchard Healthcare Research Inc - Skokie

Maryland

  • Mercy Medical Center - Baltimore
  • American Oncology Partners, PA - Bethesda

Arkansas

  • Saint Bernards Medical Center - Jonesboro

Colorado

  • Colorado West Healthcare System dba Grand Valley Oncology - Grand Junction

Idaho

  • Saint Alphonsus Regional Medical Center - Boise

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2020-02-26
Est. Completion 2027-05-20
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03937154

The ClinicalTrials.gov registry entry for NCT03937154 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 4 other Chemotherapy Induced Thrombocytopenia trials with a reported enrollment target (84% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chemotherapy Induced Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03937154 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Louisiana, California.

Frequently Asked Questions

What is clinical trial NCT03937154 about?

NCT03937154 is a clinical study titled "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer". To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

What is the current status of trial NCT03937154?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2020-02-26. Estimated completion is 2027-05-20.

What conditions does trial NCT03937154 study?

This clinical trial studies the following conditions: Chemotherapy Induced Thrombocytopenia.

What interventions are being tested in trial NCT03937154?

The interventions under investigation include: Placebo (DRUG), Romiplostim (DRUG).

Who is sponsoring clinical trial NCT03937154?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03937154 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chemotherapy Induced Thrombocytopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chemotherapy Induced Thrombocytopenia

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.